Background: Hypothyroidism is a prevalent endocrine disorder capable of affecting multiple organ systems. While somatic symptoms are common, prominent neuropsychiatric manifestations such as visual hallucinations and cognitive deficits are exceptionally rare as an initial presentation. This atypical clinical picture frequently leads to misdiagnosis as primary psychiatric disorders or neurodegenerative conditions. Case Presentation: We report the case of a 75-year-old male who presented with a three-month history of complex visual hallucinations and progressive cognitive decline. The hallucinations were notably dependent on environmental light. Initial assessments raised concerns about the neurodegenerative process. However, laboratory investigations revealed severe autoimmune hypothyroidism with high titers of anti-thyroid antibodies. Following timely levothyroxine replacement therapy, the patient achieved complete remission of visual hallucinations and significant cognitive recovery. Conclusions: This case illustrates that severe hypothyroidism can manifest as a reversible metabolic encephalopathy mimicking dementia. It underscores the importance of screening for thyroid dysfunction in elderly patients presenting with unexplained acute neuropsychiatric symptoms to ensure appropriate management.
Although cardiometabolic composite indices have shown associations with cardiovascular disease (CVD), it remains unclear whether they offer consistent risk information beyond that captured by established clinical predictors and their constituent variables. We aimed to determine whether 12 cardiometabolic composite indices provide cardiovascular risk information beyond conventional clinical factors and their individual components in adults with diabetes. The primary analyses included 1290 CHARLS participants with diabetes and no CVD at baseline, who were separated into development and fixed test sets; the principal findings were subsequently examined in an independent sample of 495 ELSA participants. Associations with incident CVD, information overlap, selection stability, model contribution, and incremental predictive performance were systematically assessed, followed by exploratory risk-stratified analyses. Estimated glucose disposal rate (eGDR) showed the most consistent risk signal. In CHARLS, each 1-standard-deviation increase in eGDR was associated with lower incident CVD risk (HR 0.65, 95% CI 0.56–0.75). Adding eGDR produced numerical increases in the C-index from 0.619 to 0.645 and the 9-year time-dependent AUC from 0.634 to 0.664, but paired bootstrap confidence intervals for these differences included zero, and eGDR did not clearly outperform its component variables. Among participants not classified as high risk, those with low eGDR comprised 36.4% of participants but accounted for 50.0% of subsequent CVD events; event proportions were 36.0% versus 20.6% (HR 1.84, 95% CI 1.12–3.04). In ELSA, higher eGDR was also associated with lower overall CVD risk, and similar numerical patterns in discrimination and residual-risk enrichment were observed, although the stroke-specific association was less clear. Overall, eGDR showed limited incremental discrimination, while exploratory risk-stratified analyses suggested possible residual-risk enrichment among participants with low eGDR; this finding requires prospective validation using prespecified thresholds.
Background/Objectives: Graves’ disease (GD) susceptibility loci are well established, but the regulatory genes and immune cell types through which they act remain unclear. Methods: We integrated FinnGen R12 GD summary statistics (3962 cases) with GTEx v10 thyroid and whole-blood cis-eQTLs using SMR, HEIDI testing and colocalization, and narrowed candidates by eQTLGen transcript-level Mendelian randomization (MR). The resulting 14 core genes were tested against FinnGen GD, UK Biobank GD, the White et al. GD meta-analysis (12,019 cases) and FinnGen Graves’ ophthalmopathy (GO) at the transcript, plasma-protein (Olink, SomaScan) and single-cell (OneK1K, 14 immune cell types) levels, using LD-aware MR and complete-region colocalization with SuSiE fine-mapping. Results: Twelve core genes were supported under FDR control in the White et al. consolidation analysis, which includes FinnGen and UK Biobank. FCRL3 was the most consistently supported gene, with risk-direction associations colocalizing with GD in thyroid, blood, plasma and lymphocyte subsets. CD40 colocalized for thyroid expression and plasma protein but not for its monocyte eQTL. MMEL1 and UBASH3A had comparable support, colocalizing in blood and T-cell subsets; ACAP1 and the 11p11 locus provided supporting evidence. The RNASET2 protein association reflected a distinct pQTL variant. No GD–GO difference survived FDR correction. Conclusions: These results provide cell-type-annotated hypotheses for validation.